GDP 366: an antineoplastic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6539985 |
| CHEMBL ID | 196363 |
| SCHEMBL ID | 232042 |
| MeSH ID | M0553277 |
| Synonym |
|---|
| kdr kinase inhibitor, 1 |
| chembl196363 , |
| biochemistry 469551 compound 3 |
| n-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-n -(3-methylphenyl)urea |
| 3-(4-{4-aminothieno[2,3-d]pyrimidin-5-yl}phenyl)-1-(3-methylphenyl)urea |
| thienopyrimidine deriv. 76 |
| bdbm8826 |
| KINOME_417 |
| 1-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-3-(3-methylphenyl)urea |
| SCHEMBL232042 |
| n-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-n'-(3-methylphenyl)urea |
| gdp366 |
| CS-7241 |
| HY-U00177 |
| 501698-03-9 |
| BCP30719 |
| gdp 366; gdp-366;1-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-3-(3-methylphenyl)urea |
| gdp 366 |
| BS-46821 |
| D81179 |
| 1-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-3-(m-tolyl)urea |
| EX-A3218 |
| BVA69803 |
| AKOS040733241 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The selected compounds 8 and 13 display 56% and 48% oral bioavailability in mice, respectively." | ( Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Ahmed, AA; Albert, DH; Bouska, JJ; Bousquet, PF; Cunha, GA; Davidsen, SK; Glaser, KB; Guo, J; Ji, Z; Li, J; Marcotte, PA; Michaelides, MR; Moskey, MD; Pease, LJ; Stewart, KD; Yates, M, 2006) | 0.33 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Serine/threonine-protein kinase PLK4 | Homo sapiens (human) | Ki | 5.1010 | 0.0003 | 0.9559 | 9.3000 | AID1798514 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0000 | 0.5369 | 10.0000 | AID254692 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0002 | 1.3173 | 10.0000 | AID254676 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | IC50 (µMol) | 0.0030 | 0.0006 | 0.5676 | 5.5450 | AID255103 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0004 | 0.3722 | 10.0000 | AID254853 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 0.0480 | 0.0006 | 0.8007 | 8.5000 | AID255118 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | IC50 (µMol) | 0.0945 | 0.0007 | 0.4708 | 10.0000 | AID1796237; AID255095; AID268776; AID471496; AID506711 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 4.2000 | 0.0002 | 0.9420 | 10.0000 | AID254660 |
| Aromatase | Homo sapiens (human) | IC50 (µMol) | 0.1830 | 0.0000 | 1.2904 | 10.0000 | AID1796237 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | IC50 (µMol) | 0.0480 | 0.0001 | 0.4912 | 10.0000 | AID255118 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 0.0020 | 0.0001 | 0.2914 | 7.0000 | AID255092; AID268774 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 4.2000 | 0.0004 | 0.3276 | 8.6200 | AID254660 |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | IC50 (µMol) | 4.2000 | 0.0008 | 0.6217 | 8.6200 | AID254660 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | IC50 (µMol) | 4.2000 | 0.0004 | 0.2863 | 8.6200 | AID254660 |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | IC50 (µMol) | 0.0130 | 0.0001 | 0.2264 | 4.9000 | AID255094; AID268775 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.0746 | 0.0000 | 0.4830 | 8.8000 | AID1796237; AID1799569; AID255111; AID255141; AID268771; AID268772; AID506710 |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | IC50 (µMol) | 0.0020 | 0.0001 | 0.3275 | 9.5480 | AID255093 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Ki | 5.1010 | 0.0002 | 1.0608 | 9.3000 | AID1798514 |
| Angiopoietin-1 receptor | Homo sapiens (human) | IC50 (µMol) | 0.4546 | 0.0004 | 0.5553 | 9.0700 | AID1796237; AID253530; AID255101; AID268773; AID506712 |
| Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | Ki | 5.1010 | 0.0010 | 1.2726 | 9.3000 | AID1798514 |
| Serine/threonine-protein kinase PLK2 | Homo sapiens (human) | Ki | 5.1010 | 0.0010 | 1.2726 | 9.3000 | AID1798514 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID506710 | Inhibition of KDR | 2007 | Journal of molecular graphics & modelling, Jul, Volume: 26, Issue:1 | 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family. |
| AID253596 | Plasma clearance observed in dog at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID268774 | Inhibition of FLT1 | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID255141 | Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID471496 | Inhibition of c-Kit by HTRF method | 2010 | European journal of medicinal chemistry, Jan, Volume: 45, Issue:1 | Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. |
| AID268772 | Inhibition of KDR by cellular assay | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID255111 | Cellular inhibition of VEGF induced human KDR phosphorylation in 3T3 murine fibroblasts | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253598 | Plasma clearance observed in monkey at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253631 | Tested for area under the curve at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID254692 | Inhibitory concentration against EGFR | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID255095 | Inhibitory concentration against cKit with 4 uM Biotin-Ahx-AEEEYFFLFA-amide for 1 hr at ambient temperature | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253530 | Inhibitory concentration against TIE2 using biotinylated poly(Glu-Tyr) (10 ng/well) for 1 hr at ambient temperature | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253562 | Bioavailability observed in monkey at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID268780 | Oral bioavailability in mouse at 3 mg/kg, iv | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID268778 | Volume of distribution in mouse at 3 mg/kg, iv | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID254853 | Inhibitory concentration against cMET receptor tyrosine kinase | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253612 | Volume of distribution observed in monkey at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID268776 | Inhibition of CKIT | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID268775 | Inhibition of FLT4 | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID253599 | Plasma clearance observed in CD-1 mouse at dose of intravenously at 3 mg/kg and orally at 10 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID254676 | Inhibitory concentration against LCK | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253635 | Tested for area under the curve at dose of intravenously at 3 mg/kg and orally at 10 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID268779 | Clearance in mouse at 3 mg/kg, iv | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID253769 | Plasma eliminationhalf-life observed in monkey at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID255700 | In vivo effective dose required to inhibit uterine edema induced by 17 beta-estradiol (20-25 ug/mouse) in BALB/c female mouse | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253615 | Compound tested for volume of distribution in CD-1 mouse at dose of intravenously at 3 mg/kg and orally at 10 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID255103 | Inhibitory concentration against CSF1R with 4 uM Biotin-Ahx-AEEEYFFLFA-amide for 1 hr at ambient temperature | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID268781 | AUC in mouse at 10 mg/kg, po | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID506711 | Inhibition of cKIT | 2007 | Journal of molecular graphics & modelling, Jul, Volume: 26, Issue:1 | 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family. |
| AID253768 | Plasma eliminationhalf-life observed in dog at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID255093 | Inhibitory concentration against FLT3 with 4 uM Biotin-Ahx-AEEEYFFLFA-amide for 1 hr at ambient temperature | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID255094 | Inhibitory concentration against FLT4 with 4 uM Biotin-Ahx-AEEEYFFLFA-amide for 1 hr at ambient temperature | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253556 | Bioavailability observed in dog at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID255118 | Cellular inhibition of VEGF induced human PDGFR phosphorylation in 3T3 murine fibroblasts | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID268771 | Inhibition of KDR | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID255101 | Inhibitory concentration against Tie2 using biotinylated poly(Glu-Tyr) (10 ng/well) for 1 hr at ambient temperature | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253611 | Volume of distribution observed in dog at a dose of both intravenously and orally at 5 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID255092 | Inhibitory concentration against FLT1 with 4 uM Biotin-Ahx-AEEEYFFLFA-amide for 1 hr at ambient temperature | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID254660 | Inhibitory concentration against FGFR | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID506712 | Inhibition of Tie2 | 2007 | Journal of molecular graphics & modelling, Jul, Volume: 26, Issue:1 | 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family. |
| AID253566 | Oral bioavailability in mouse (CD-1) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID253770 | Plasma eliminationhalf-life observed in CD-1 mouse at dose of intravenously at 3 mg/kg and orally at 10 mg/kg | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID268773 | Inhibition of TIE2 | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID268777 | Half life in mouse at 3 mg/kg, iv | 2006 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16 | Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. |
| AID493040 | Navigating the Kinome | 2011 | Nature chemical biology, Apr, Volume: 7, Issue:4 | Navigating the kinome. |
| AID1796237 | Homogeneous Time-resolved Fluorescence (HTRF) Assay from Article 10.1021/jm050458h: \\Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.\\ | 2005 | Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19 | Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. |
| AID1798514 | PLK Kinase Assay from Article 10.1021/bi7008745: \\Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.\\ | 2007 | Biochemistry, Aug-21, Volume: 46, Issue:33 | Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. |
| AID1799569 | Kinase Inhibition Assay from Article 10.1111/j.1747-0285.2007.00488.x: \\The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.\\ | 2007 | Chemical biology & drug design, Mar, Volume: 69, Issue:3 | The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.90) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||